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The increasing manufacture and use of products based on nanotechnology raises concerns for both workers and
consumers. Various studies report induction of pulmonary inflammation after inhalation exposure to nanoparticles,
which can vary in aspects such as size, shape, charge, crystallinity, chemical composition, and dissolution rate. Each
of these aspects can affect their toxicity, although it is largely unknown to what extent. The aim of the current
review is to analyse published data on inhalation of nanoparticles to identify and evaluate the contribution of their
physicochemical characteristics to the onset and development of pulmonary inflammation. Many physicochemical
characteristics of nanoparticles affect their lung deposition, clearance, and pulmonary response that, in
combination, ultimately determine whether pulmonary inflammation will occur and to what extent. Lung
deposition is mainly determined by the physical properties of the aerosol (size, density, shape, hygroscopicity) in
relation to airflow and the anatomy of the respiratory system, whereas clearance and translocation of nanoparticles
are mainly determined by their geometry and surface characteristics. Besides size and chemical composition, other
physicochemical characteristics influence the induction of pulmonary inflammation after inhalation. As some
nanoparticles dissolve, they can release toxic ions that can damage the lung tissue, making dissolution rate an
important characteristic that affects lung inflammation. Fibre-shaped materials are more toxic to the lungs
compared to spherical shaped nanoparticles of the same chemical composition. In general, cationic nanoparticles
are more cytotoxic than neutral or anionic nanoparticles. Finally, surface reactivity correlates well with observed
pulmonary inflammation. With all these characteristics affecting different stages of the events leading to pulmonary
inflammation, no unifying dose metric could be identified to describe pulmonary inflammation for all nanomaterials,
although surface reactivity might be a useful measure. To determine the extent to which the various characteristics
influence the induction of pulmonary inflammation, the effect of these characteristics on lung deposition, clearance,
and pulmonary response should be systematically evaluated. The results can then be used to facilitate risk
assessment by categorizing nanoparticles according to their characteristics.
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Risk assessmentIntroduction
In recent years, a large number of nanotechnology-
enabled products have entered the global marketplace.
In March 2011, the Nanotechnology Consumer Products
Inventory contained 1317 products or product lines
from over 30 countries, a growth of nearly 521% (from
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unless otherwise stated.released in March 2006 [1]. Exposure to nanomaterials
is on the rise, and because of uncertainty regarding their
toxic characteristics, concerns have arisen that such ma-
terials pose new health risks for consumers, workers,
and the environment.
An adequate risk assessment of nanomaterials requires
information on both the exposure and hazard of their
component particles. Inhalation is considered to be an im-
portant route of exposure to nanoparticles [2,3], especially
in occupational settings. Many products, such as sprays,
may likewise lead to inhalation by consumers [4,5]. With
regard to hazard, numerous in vitro and in vivo studiesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nanoparticles causes adverse effects. The most reported
effect is pulmonary inflammation, largely indicated by an
influx of neutrophils that can be observed in the broncho-
alveolar lavage fluid in vivo and the induction of inflam-
matory cytokines in in vitro lung models eg. [6-13].
Nanomaterials are composed of primary and agglo-
merated particles that can vary in size, shape, charge,
crystallinity, chemical composition and other charac-
teristics, and this variety will increase even further in the
future [14]. All these characteristics have been suggested
to affect the toxicity of nanomaterials, but not all exis-
ting and emerging types of nanomaterials can be tested
separately in studies to evaluate their safety. The current
review therefore seeks to identify trends regarding their
characteristics and pulmonary inflammation, as a key
hazard indicator, by analysing published data on inha-
lation of nanoparticles. Ideally, this includes in depth
analysis of characteristics that influence the mechanism
underlying pulmonary inflammation e.g. that affect
chemotactic signalling. Unfortunately, little information
exists to elucidate the role of specific particle properties
on details of the mechanism such as chemotactic signals.
For this reason, we have limited our analysis to more
generally reported effects of pulmonary inflammation
and phagocytosis at a larger scale. The exposure assess-
ment of nanomaterials, which is of major importance for
the risk assessment of nanomaterials, is out of the scope
of this review. As the induction of pulmonary inflamma-
tion results from a combination of their deposition,
clearance, and interactions in the lungs, the characteris-
tics influencing one or more of these processes will be
discussed using data of peer reviewed papers. Ultimately,
these results can be used to design safer nanomaterials
and to identify those that need to be investigated further
in terms of their health risks. For the risk assessment of
nanomaterials, knowledge on toxicity-determining cha-
racteristics will help to categorise nanomaterials into
hazard groups according to these characteristics.
Comparison across studies is often difficult due to the
use of different experimental protocols and choice of
endpoints, which largely influences the results. There-
fore, our approach was to focus on investigations of
multiple nanoparticles differing in one physicochemical
characteristic within the same in vivo study. These stu-
dies are summarised in Table 1. We are aware of the fact
that some studies use rather high exposures. Since there
is no scientific consensus on when exposures are no
longer realistic, and for the sake of including as much
information as possible, we did include these studies in
our review. In addition, we included both inhalation and
intratracheal instillation studies. Since the dose rate
together with the clearance rate will be the main driver
for the retained dose, intratracheal instillation may leadto different effects than when using inhalation of aero-
sols; when available, the retained doses in the lungs are
included.
Deposition of nanoparticles in the lungs
A primary or individual nanoparticle (also called “ultrafine
particle”) has a mean primary diameter of <100 nm,
compared to >1 μm for a microparticle (also called “fine
particle”). Primary particles tend to agglomerate, or aggre-
gate, into larger particles. As they travel through the air
from the point of generation to the point of exposure, the
size of the primary and agglomerated particles determines
their lung deposition pattern. (Figure 1) [45-47]. When
nanoparticles are agglomerated in air, measurements of
nanoparticle size will give the size of the agglomerates and
not the primary particles [48]. The size of the agglomer-
ates can be measured with different techniques, depending
on the size of the agglomerates. Optical particle sizers
(OPS) and aerodynamic particle sizers (APS) can measure
the aerodynamic particle size ranging from 300 nm to
10 μm or 500 nm to 10 μm, respectively [49,50]. The aero-
dynamic particle size is mostly given as a mass median
aerodynamic diameter (MMAD). Differential mobility
analysers (DMA) and scanning mobility particle sizers
(SMPS) can measure the electrical mobility diameter of
particles ranging from 2.5 nm to 1 μm, depending on the
type of SMPS used. The electrical mobility diameter is
mostly given as a count median diameter (CMD). The
aerodynamic size depends not only on the physical size of
the particles but also on the density of the particles, while
the electrical mobility size depends on the physical size
alone [50].
Nanoparticles with a primary or agglomerate particle
size between 10 and 100 nm will deposit more efficiently
in the alveolar region compared to particles with an ag-
glomerate particle size between 0.1 and 1 μm [45-47,51].
In the alveoli the airflow is minimal, therefore, for nano-
particles between 10 and 100 nm, the mechanism of
deposition in the lungs is diffusion [52]. Several in vivo
inhalation studies [10,16,17,21] show that particles of
smaller agglomerate size deposit more efficiently in the
alveolar region than those of larger agglomerate size.
Particles that differ in primary particle size but have the
same agglomerate diameter show similar deposition frac-
tions [18,22,27,32]. As stated above, for agglomerated
nanoparticles with an aerodynamic size above 300 nm,
the density affects deposition. For these large agglo-
merates, increasing the density increases their deposition
in the lungs, including in the alveolar region (Figure 1).
It should be noted that the density of agglomerated par-
ticles is lower than the material density of the particles
itself. Shape is also a factor. Primary and agglomerated
nanoparticles occur in forms such as spheres, rods,
fibres, wires, belts, triangles, and platelets. Shapes with a
Table 1 Inhalation studies investigating the effect of nanomaterial characteristics on lung deposition, clearance, and/or pulmonary inflammation
Nanoparticle
characteristic
studied
Reference Chemical
composition
Primary particle size Agglomerate particle
size in air
Exposure time and type Lung deposition,
clearance, and
translocation
Lung inflammation
Agglomerate size Ho et al.
2011 [15]
Zinc oxide Not reported 35 nm CMD1 6 hours inhalation Dose-dependent
pulmonary inflammation.
Exposure concentration:
2.4, 3.7, 12.1 mg/m3 for
the 35 nm particles and
7.2, 11.5, 45.2 mg/m3 for
the 250 nm particles.
250 nm CMD
Agglomerate size Kreyling et al.
2002 [16]
Radio-labelled
Iridium
Not reported 15 nm CMD 1 hour inhalation: 0.6 μg
15 nm; 6.0 μg 80 nm
Larger deposited fraction
of 15 nm compared to
80 nm particles. Similar
clearance kinetics via
gastro-intestinal tract.
Translocation very low,
but higher for the 15 nm
compared to the 80 nm
particles.
80 nm CMD
Agglomerate size Kreyling et al.
2009 [17]
Radio-labelled
Iridium
2 – 4 nm 20 nm CMD 1 hour inhalation: 0.6 μg
15 nm; 6.0 μg 80 nm
Translocation of 20 nm
Iridium particles is larger
compared to 80 nm
Iridium particles
80 nm CMD Translocation of Iridium
particles is higher
compared to similar sized
carbon particles.
Chemical
composition
Iridium-labelled
Carbon
5 – 10 nm 25 nm CMD
Agglomerate size Noël et al.
2012 [18]
Titanium dioxide 5 nm 30 and 185 nm
agglomerates (2 mg/m3)
31 and 194 nm
agglomerates (7 mg/m3)
6 hours inhalation: 2 mg/
m3 and 7 mg/m3
Similar lung deposition of
small and large
agglomerates.
Exposure to both small
and large agglomerates
at 7 mg/m3 resulted in
adverse effects. Exposure
to the large agglomerates
results in a significant
increase in neutrophils in
the lungs, while the small
agglomerates did not.
Agglomerate size Oberdörster
et al. 2000 [10]
Platinum Not reported 18 nm CMD 6 hours inhalation:
100 μg/m3 platinum and
carbon; 40 μg/m3 Teflon
Ultra-fine particles all
reach interstitial sites after
translocation.Carbon 26 nm CMD
Teflon 18 nm CMD
Agglomerate size Oberdörster
et al. 2000 [10]
Teflon Not reported Starting with 18 nm CMD,
size increasing over time
6 hours inhalation:
~50 μg/m3
Particles increased in size
over time while particle
number decreased; only
freshly generated fumes
(<100 nm) caused
inflammation.
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Table 1 Inhalation studies investigating the effect of nanomaterial characteristics on lung deposition, clearance, and/or pulmonary inflammation (Continued)
Charge and
solubility
Cho et al.
2012 [19]
Silver 91.9 nm Not applicable Intratracheal instillation:
150 cm2/rat
Instillation of aluminum
oxide, both cerium
dioxides, cobalt oxide,
both cupper oxides,
nickel oxide, and both
zinc oxides induced
significant pulmonary
inflammation, whereas
instillation of the other
nanoparticles did not.
Aluminum oxide 6.3 nm
Cerium dioxide 9.7 and 4.4 nm
Cobalt oxide 18.4 nm
Chromium oxide 205 nm
Copper oxide 23.1 and 14.2 nm Regarding the high-
solubility nanoparticles,
the inflammogenicity of
copper oxide and zinc
oxide was derived from
their soluble ions. Other
parameters showed a
poor correlation with
inflammation potential of
nanoparticles.
Magnesium oxide 15 nm
Nickel oxide 5.3 nm
Silicon dioxide 6.2 nm
Titanium dioxide 5.6 and 30.5 nm
Zinc oxide 10.7 and 137 nm
Charge Choi et al.
2010 [20]
Quantum dots
(Zwitterionic,
polar, anionic,
cationic)
5 – 38 nm Not applicable Intratracheal instillation A size threshold
of ~34 nm determines
whether there is rapid
translocation of
nanoparticles. Below
34 nm, surface charge is a
major factor influencing
translocation, with
zwitterionic, anionic and
polar surfaces being
permissive and cationic
surfaces being restrictive.
Silica (Polar) 56 – 320 nm
Polystyrene
(Zwitterionic,
polar, anionic)
7 – 270 nm
Chemical
composition
Heinrich et al.
1995 [21]
Diesel exhaust - 0.25 μm MMAD2 2 year inhalation (rats) Deposition, retention and
total lung burden of
diesel exhaust particles
was highest compared to
carbon black and
titanium dioxide.
Clearance was reduced in
all groups; mostly
reduced in group
exposed to highest
concentration of diesel
exhaust.
Similar effects in all
particle groups; carbon
black induced the most
lung tumours. Exposure
concentration: 0.8, 2.5, 4.5,
7 mg/m3 diesel exhaust,
11.6 mg/m3 carbon black
and 10 mg/m3 titanium
dioxide.
Carbon black 14 nm 0.64 μm MMAD 1 year inhalation (mice)
Titanium dioxide 15 – 40 nm 0.80 μm MMAD
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Table 1 Inhalation studies investigating the effect of nanomaterial characteristics on lung deposition, clearance, and/or pulmonary inflammation (Continued)
Chemical
composition
Landsiedel et al.
2010 [22]
Titanium dioxide 40 nm (A) - 5 days inhalation: 2, 10,
50 mg/m3 TiO2 (B); 0.5,
2.5, 10 mg/m3 ZrO2, CeO,
SiO2, ZnO, CB; 0.1, 0.5,
2.5 mg/m3 MWCNT
Similar deposition of the
particles. Only exposure
to anatase titanium
dioxide (B) resulted in
particle overload in the
lungs.
Titanium dioxide, cerium
oxide, zinc oxide and
MWCNT induced dose-
dependent pulmonary
inflammation. The effects
of MWCNT were most
severe and progressive.
Zirconium dioxide, silicon
dioxide and carbon black
did not induce
inflammation.
Titanium dioxide 25 nm (B) 0.9 μm MMAD
Zirconium dioxide 40 nm 1.5 μm MMAD
Cerium oxide 40 nm 0.8 μm MMAD
Zinc oxide 60 nm 0.9 μm MMAD
Silicon dioxide 15 nm 1.2 μm MMAD
Carbon black 27 nm 0.8 μm MMAD
MWCNT - 1.5 μm MMAD
Chemical
composition
Wang et al.
2010 [23]
Iron oxide 30 nm Not reported Spraying in the nose,
twice daily for 3 days:
8.5 mg/kg bw Fe2O3 and
2.5 mg/kg bw ZnO
12 hours after exposure,
zinc was detected in liver;
36 hours after exposure,
iron was detected in liver
and zinc in the kidneys.
Zinc oxide particles
caused more severe
changes in the liver while
iron oxide caused more
severe lung lesions.
Zinc oxide 20 nm
Hydrophobicity Arts et al.
2007 [24]
Pyrogenic silica Not reported 2 – 3 μm MMAD 5 days inhalation: 1, 5
and 25 mg/m3
Pyrogenic silica induced
the most pronounced
pulmonary inflammation
compared to the other
silica types.
Silica gel
Precipitated silica
Hydrophobicity Reuzel et al.
1991 [25]
Hydrophilic silica 12 nm 1 – 120 μm MMAD 13 weeks inhalation: 1, 6,
and 30 mg/m3
The 12 nm hydrophilic
silica particles were more
quickly cleared from the
lungs compared to the
other silica types.
Hydrophilic 12 nm
(pyrogenic) silica induced
more pulmonary
inflammation compared
to the other silica’s.
Hydrophobic silica 12 nm
Hydrophilic silica 18 nm
Primary particle
size
Balasubramanian
et al. 2013 [26]
Gold 7 nm 45.6 CMD 15 days inhalation: 0.086
-0.9 mg/m3 7 nm; 0.053 –
0.57 mg/m3 20 nm
7 nm gold NPs deposited
in the brain, blood, small
intestine and pancreas at
greater mass
concentration compared
to 20 nm gold NPs.
Clearance of the 20 nm
particles is more effective
compared to the 7 nm
particles.
20 nm 41.7 CMD
Primary particle
size
Geraets et al.
2012 [27]
Cerium oxide 5 – 10 nm 1.02 μm MMAD 28 days inhalation:
11 mg/m3 5–10 nm;
20 mg/m3 40 nm; 55 mg/
m3 < 5000 nm
Similar deposition in all
groups; slow clearance in
all groups; even slower
clearance in 5 – 10 nm
group. Very low
translocation to
secondary organs.
40 nm 1.17 μm MMAD
<5000 nm 1.4 μm MMAD
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Table 1 Inhalation studies investigating the effect of nanomaterial characteristics on lung deposition, clearance, and/or pulmonary inflammation (Continued)
Primary particle
size
Gosens et al.
2010 [28]
Gold 50 nm 200 nm agglomerated Intratracheal instillation:
1.6 mg/kg bw
Mild pulmonary
inflammation; more
effects for single 250 nm
particles than for single
50 nm particles.
250 nm 770 nm agglomerated
Primary particle
size
Gosens et al.
2013 [29]
Cerium oxide 5 – 10 nm 1.02 μm MMAD 28 days inhalation:
11 mg/m3 5–10 nm;
20 mg/m3 40 nm; 55 mg/
m3 < 5000 nm
All materials induced
dose-dependent pulmonary
inflammation to the same
extent.
40 nm 1.17 μm MMAD
<5000 nm 1.4 μm MMAD
Primary particle
size
Horie et al.
2012 [30]
Nickel oxide 100 nm Not applicable Intratracheal instillation:
0.2 mg/0.4 ml
Nano-sized nickel
particles induced
inflammation and
oxidative stress, while
larger sized particles did
not.
600 – 1400 nm
Chemical
composition
Titanium dioxide 7 nm
Nano-sized nickel
particles induced
inflammation and
oxidative stress, while the
titanium dioxide particles
did not.
200 nm
Primary particle
size
Kobayashi et al.
2009 [31]
Titanium dioxide 4.9 nm Not applicable Intratracheal instillation:
1.5 mg/kg
Smaller particles induced
greater inflammatory
response at the same
mass dose.
23.4 nm
154.2 nm
Primary particle
size
Oberdörster et al.
1994 [32]
Titanium dioxide 20 nm 0.71 μm MMAD 12 weeks inhalation:
24 mg/m3 20 nm TiO2;
22 mg/m3 250 nm TiO2
Similar deposition in both
groups. After deposition,
disaggregation into
smaller agglomerates.
Retention halftime for
20 nm particles is longer
compared to 250 nm
particles.
250 nm 0.78 μm MMAD
Primary particle
size
Oberdörster et al.
2000 [10]
Platinum Not reported 13 nm CMD 6 hours inhalation:
~110 μg/m3
Uptake of ultra-fine
particles by lung
macrophages was lower
compared to larger sized
particles.
Primary particle
size
Oberdörster et al.
2000 [10]
Titanium dioxide 20 nm Not applicable Intratracheal instillation Both in rats and mice, 20 nm particles induced
inflammation at lower mass dose compared to
250 nm particles. Exposure concentrations for the
20 nm particles: 31, 125, 500 μg in rats and 6, 25,
100 μg in mice. Exposure concentrations for the
250 nm particles: 125, 500, 2000 μg in rats and 25,
100, 400 μg in mice.
250 nm
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Table 1 Inhalation studies investigating the effect of nanomaterial characteristics on lung deposition, clearance, and/or pulmonary inflammation (Continued)
Primary particle
size
Pauluhn et al.
2009 [13]
Aluminum
oxyhydroxide
10 nm 1.7 μm MMAD 4 weeks inhalation: 0.4, 3
and 28 mg/m3
Translocation of 40 nm
particles was higher
compared to the 10 nm
particles.
Both particles induced
pulmonary inflammation
to the same extent.40 nm 0.6 μm MMAD
Primary particle
size
Roursgaard et al.
2010 [33]
Quarts 100 nm Not applicable Intratracheal instillation:
50 μg
Both particles induced
pulmonary inflammation
to the same extent.1.6 μm
Primary particle
size
Sadauskas et al.
2009 [34]
Gold 2 nm (12 μg/ml) Not applicable 5 intratracheal instillations
within 3 weeks: 50 μl
Gold particles of all sizes
detected in alveolar
macrophages;
translocation very low,
but seems higher for
2 nm particles compared
to larger sized particles.
40 nm (58 μg/ml)
100 nm (60 μg/ml)
Primary particle
size
Sayes et al.
2010 [35]
Silica Not reported 37 nm CMD 1 or 3 day inhalation: 1.8
and 86 mg/m3
No induction of
pulmonary inflammation.
83 nm CMD
Primary particle
size
Stoeger et al.
2006 [36]
Carbonaceous
nanoparticles
Six particles ranging
from 10 – 50 nm
Not applicable Intratracheal instillation: 5,
20 and 50 μg
Dose-dependent
pulmonary inflammation;
smaller nanoparticles
induced more severe
effects compared to
larger nanoparticles.
Primary particle
size
Zhu et al.
2008 [37]
Ferric oxide 22 nm Not applicable Intratracheal instillation:
0.8 and 20 mg/kg bw
Both particles induced
pulmonary inflammation
and oxidative stress to
the same extent.
280 nm
Shape Porter et al.
2012 [38]
Titanium dioxide
spheres (anatase)
<70 – 200 nm Not applicable Pharyngeal aspiration: 15,
30 μg spheres; 7.5, 15,
30 μg nanobelts of 3 μm;
1.88, 7.5, 15, 30 μg
nanobelts of 9 μm
Similar deposition for
different shaped particles.
Lung burden after
exposure to nano-spheres
was significantly lower
compared to exposure to
long nano-belts 112 days
after exposure: impaired
clearance of nano-belts.
Dose-dependent
pulmonary inflammation
in the animals exposed to
titanium dioxide nano-
belts. The longer nano-
belts caused more severe
pulmonary inflammation
compared to the shorter
ones. Shape and length
affect pulmonary
responses.
Titanium dioxide
nano-belts
(anatase)
Length:3 μm (1 – 5 μm), width: 70 nm (40 – 120 nm)
Length: 9 μm (4 – 12 μm), width: 110 nm (60 – 140)
Shape Schinwald et al.
2012 [39]
Silver nanowires 3 μm length, 115 nm diameter Pharyngeal aspiration:
10.7, 17.9, 35.7, and 50 μg
for 3, 5, 10 and 14 μm
fibres, respectively
Length dependent
restriction of macrophage
locomotion. Fibre-
length ≥ 5 μm resulted in
impaired motility.
Length dependent
inflammatory response in
the lungs with threshold
at a fibre length of
14 μm. Shorter fibres
elicited no significant
inflammation.
5 μm length, 118 nm diameter
10 μm length, 128 nm diameter
14 μm length, 121 nm diameter
28 μm length, 120 nm diameter
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Table 1 Inhalation studies investigating the effect of nanomaterial characteristics on lung deposition, clearance, and/or pulmonary inflammation (Continued)
Shape Schinwald et al.
2012 [40]
Graphene
platelets
5.6 μm projected area diameter Pharyngeal aspiration and
intrapleural instillation:
50 μg
Prolonged retention of
graphene platelets in the
pleural space.
Exposure to graphene
nanoplatelets caused
pulmonary inflammation,
while exposure to carbon
black did not.
Carbon black 10 nm
Shape Ma-Hock et al.
2013 [41]
Multi-walled
carbon nanotubes
15 nm, fiber-shape 0.5 μm CMD 5 days inhalation: 0.1, 0.5,
and 2.5 mg/m3 MWCNT,
0.5, 2.5, and 10 mg/m3
graphene, nanoplatelets
and CB
The lung deposition was
calculated to be 0.03 mg/
lung MWCNT, 0.3 mg/
lung graphene, 0.2 mg/
lung graphite
nanoplatelets, and
0.4 mg/lung carbon black.
Pulmonary inflammation
was induced after
exposure to multi-walled
carbon nanotubes at all
concentrations, and
exposure to graphene at
10 mg/m3. The other
exposures did not induce
pulmonary inflammation.
The lung burden did not
correlate to the observed
toxicity.
Graphene Up to 10 μm, flake 0.6 μm CMD
Graphite
nanoplatelets
Up to 30 μm, flake 0.4 μm CMD
Carbon black 50 – 100 nm 0.4 μm CMD
Solubility Cho et al.
2011 [42]
Zinc oxide 10.7 nm 137 nm Not applicable Intratracheal instillation:
50 and 150 cm2/rat
Zinc oxide particles
caused severe pulmonary
inflammation probably
caused by zinc ions
released from rapid
dissolution of inside
phagolysosomes.
Nickel oxide 5.3 nm
Titanium dioxide 30.5 nm
Solubility Cho et al.
2012 [43]
Nickel oxide 10 – 20 nm Not applicable Intratracheal instillation:
30, 100, 300 cm2/ml NiO;
3, 10, 30 cm2/ml ZnO and
CuO
Pulmonary inflammation
is caused by nickel oxide
nanoparticles and not the
ions, zinc oxide and
copper oxide
nanoparticles caused
particle-specific eosinophil
recruitment. In vitro, zinc
and copper ions caused
the observed adverse
effects.
Zinc oxide <10 nm
Copper oxide (and
their aqueous
extracts)
<50 nm
Surface reactivity Van Ravenzwaay
et al. 2009 [44]
Titanium dioxide
(70% anatase, 30%
rutile)
20 – 30 nm 1.0 μm MMAD 5 days inhalation: 88 mg/
m3 20–30 nm TiO2;
274 mg/m3 200 nm TiO2;
96 mg/m3 Quartz
Both titanium particles
induced reversible effects,
while the effects caused
by quartz remained.
Quartz induced the most
prominent pulmonary
inflammation while the
surface area of deposition
was the lowest.
Chemical
composition
Titanium dioxide
(rutile)
200 nm 1.1 μm MMAD
Quartz 1.2 μm MMAD
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Table 1 Inhalation studies investigating the effect of nanomaterial characteristics on lung deposition, clearance, and/or pulmonary inflammation (Continued)
Surface reactivity Warheit et al.
2007 [11]
Nano-titanium Not reported 140 nm Intratracheal instillation: 1
and 5 mg/kw bw
Only the titanium dioxide
particles with the highest
surface reactivity induced
pulmonary inflammation.
Nano-titanium 130 nm
Fine titanium 380 nm (size in water)
Surface reactivity Warheit et al.
2007 [12]
Nano-Quartz 50 nm Not applicable Intratracheal instillation: 1
and 5 mg/kg bw
Pulmonary inflammation
was not dependent on
particle size but
correlated well with the
haemolytic potential of
the particles.
Nano-Quartz 12 nm
Fine Quartz 300 nm
1CMD: count median diameter.
2MMAD: mass median aerodynamic diameter.
Studies are listed according to the nanoparticle characteristic studied, in alphabetical order.
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Figure 1 Deposition of particles in different regions of the lung depends on particle size and density. Particle size ranges from 1 nm to
100 μm, particle density tested: 0.1 g/cm3 (left panel), 1.0 g/cm3 (centre panel) and 10.0 g/cm3 (right panel) (Simulation made in Multiple Pathway
Particle Dosimetry Model V2.1 Copyright ARA 2009, based on human oronasal-normal augmenter breathing). The figure shows the deposition of
inhaled particles in the extra-thoracic region (black line), the tracheobronchial region (grey line), and the alveolar region (red line). In the alveolar region,
the deposition is the highest for nanoparticles with a primary or agglomerate particle size between 10 nm and 100 nm, regardless of the density. For
particles with a primary or agglomerate size between 100 nm and 1 μm, the (agglomerate) density influences the deposition in the lungs: in this size
range particles/agglomerates with a higher density will deposit more efficiently in the alveolar region compared to particles/agglomerates with a
lower density.
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that is about three times their actual diameter; long fi-
bres can deposit in the upper airways due to interception
by touching the surface of the airways [53,54].
For particles to induce pulmonary inflammation, they
must deposit in the alveolar region. When the agglome-
rate size of nanoparticles is <100 nm but above 10 nm, a
considerable part of them will deposit in the alveolar re-
gion (about 30% of the particles) [45,46,55]. Although
below 30 nm, the deposition shifts from the alveoli more
towards the tracheobronchial region.
Using the above information, one can predict the dose
of nanomaterials in the lung by using the Multiple Path-
way Particle Dosimetry model (MPPD model). The model
uses the morphology of the lung, respiratory conditions,
and particle size (either CMD or MMAD), particle dens-
ity, and exposure concentration to predict deposition in
the various regions of the lung [51]. The exposure concen-
tration determines the total amount of the nanoparticles
that will deposit in the different regions of the lungs; it
does not directly influence the deposition fraction in dif-
ferent regions of the lungs. It is important to note that the
MPPD model gives an approximation of the deposition of
particles in the lungs and results should be viewed with
caution. For example, Figure 1 shows extra-thoracic
deposition of 1 nm particles and no tracheobronchial or
alveolar deposition in humans during oronasal breathing,
while there is substantial deposition of 1 nm particles in
the tracheobronchial region in humans during oral brea-
thing (about 24%) [46]. In addition, nanoparticles can
be polydispersed in the air, resulting in a range ofagglomerate sizes within a cloud of nanoparticles. When
selecting CMD in the MPPD model, the polydispersity of
the particles is not taken into account and the resulting
lung deposition pattern should be interpreted as an esti-
mation with uncertainties.
Another complicating factor is that nanoparticle ag-
glomerate size changes over time by coagulation in air.
The process is predominantly determined by Brownian
motion and depends on the concentration of particles as
they travel from site of generation to site of exposure; it
also depends on the time required to reach the exposure
site [56]. Nanomaterials are generated with a certain
primary particle size but then tend to agglomerate,
resulting in a lower number of particles with an increas-
ing agglomerate size. The higher the particle number at
generation, the faster these agglomerates are formed:
nanoparticles of 30 nm primary size at a number con-
centration of 107 particles/cm3 are stable for a maximum
of 10 seconds, while the same nanoparticles at a number
concentration of 106 particles/cm3 are stable for a max-
imum of 100 seconds [57]. With longer travel times, the
agglomerates increase in size. The speed and extent of
agglomeration also depend on nanoparticle characteris-
tics like surface charge, type of coating, and hygrosco-
picity. Particles with the same surface charge repel each
other, whereas neutral particles more easily agglomerate.
Similar, coatings can cause nanoparticles to repel or
attract. Hygroscopicity describes particle response to
water molecules in the environment, depending on
the relative humidity. For example, they may attract
molecules and grow many times their original size at
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own water content to evaporation, shrinking in size, at
decreasing relative humidity.
When the influence of particle size is investigated, it
should be measured as closely as possible to the site of ex-
posure and not at the site of generation as a primary
nanoparticle may constantly change its agglomerate size.
After deposition of inhaled nanoparticles, agglomeration
usually plays a minor role since the peripheral lung surface
area is so large that the probability of two nanoparticles
landing on each other is rather low for a diffusion-driven
deposition. This is in contrast to deposition patterns of
larger particles, which often congregate in ‘hot-spots’. The
binding kinetics of proteins as influenced by nanoparticle
charge and other physicochemical properties of the sur-
face is the more important mechanism after deposition. In
animal studies the lung deposition can be measured, while
in humans the deposition of particles in the different re-
gions of the lungs can be modelled by the MPPD model.
The results of the MPPD model should be interpreted
with caution, as they are an estimation of what happens in
reality.
Clearance of nanomaterials from the lungs
When nanoparticles are not exhaled, but deposited in the
respiratory tract, there are several transport pathways to
clear them. The sooner particles are cleared from the
lungs, the smaller the likelihood that pulmonary inflam-
mation will develop. The most prevalent mechanism for
solid particle clearance in the alveolar region is mediated
by alveolar macrophages, through phagocytosis [52]. Once
the macrophages have taken up particles, they move gra-
dually toward the mucociliary escalator and are subse-
quently swallowed and cleared from the body through the
gastrointestinal tract.
The retention time of particles in the lung depends on
the deposition site and the interaction of particles with the
inner lung surface. Particles that deposit in the conducting
airways have a short retention time due to efficient muco-
ciliary and cough clearance. The retention time increases
when particles deposit deeper in the lungs, given the in-
creased pathway length and decreased mucous velocity
[59]. For microparticles, the retention half-time in the
alveolar region is about 70 days in rats and up to 700 days
in humans [52]. For nanoparticles, the retention half-time
tends to be longer because they can deposit in the alveolar
region when their (agglomerate) size is between 10 nm
and 100 nm. Even with a short retention time and com-
plete phagocytosis by alveolar macrophages, pulmonary
inflammation may still occur, as macrophages are well
known for the release of pro-inflammatory mediators in
response to the uptake of nanoparticles [60,61].
If not cleared by phagocytosis, nanoparticles can reach
pulmonary interstitial sites from which they are transportedto the local lymph nodes. In addition, translocation of par-
ticles into the blood circulation can occur by crossing the
lung barrier in the alveolar region [62]. Subsequently, the
particles are cleared from the body by the liver, gastro-
intestinal tract, or kidneys. However, translocated particles
may be able to reach organs beyond the lung, where they
can accumulate, and might cause damage. When the de-
position of particles in the lung overwhelms the clearance
mechanisms of the lung, this may result in a retained lung
burden or accumulation of particles in the lung, which is
greater than expected from linear kinetics. This situa-
tion is called lung particle overload [7,63-66]. In rats,
particle overload may result in sustained inflammation,
fibrosis and induction of lung tumours, but the evi-
dence on whether this situation occurs in humans is in-
conclusive [67].
For all these lung clearance and transport pathways,
several nanomaterial characteristics are of influence.
Particle size
Size-dependent differences are important in the cascade
of events leading to effective macrophage-mediated clear-
ance. After deposition, agglomerates can disagglomerate
into the primary particles [26,32], or primary particles can
agglomerate after contact with the lung lining fluid [68].
At the site of deposition, the lung is thus exposed to large
agglomerates, smaller agglomerates, or primary particles,
as can be verified by transmission electron microscopy
(TEM). Microparticles or large nanoparticle agglomerates,
with a particle/agglomerate size of >1 μm, are easy for
macrophages to phagocytize [59], but single nanoparticles
and small agglomerates are more difficult [69-71], and the
smaller the nanoparticles, the less efficient their clearance
[72]. Within 24 hours after exposure, alveolar macro-
phages phagocytize only 20% of nanoparticles compared
to 80% of microparticles [52]. The nanoparticles that are
not phagocytized are retained in the interstitium and in
epithelial cells. Several in vivo inhalation studies report
decreased clearance of nanoparticles from the lungs
compared to larger-sized particles, resulting in increased
retention time [32,69,70,73]. Increased retention gives
nanoparticles the opportunity to translocate through the
lung barrier. One study found low amounts (<0.2% of the
inhaled dose) of cerium oxide in secondary organs [27].
Another study reported no difference in clearance rate be-
tween 15 nm and 80 nm radio-labelled iridium particles in
rats. However, the translocation of the 15 nm particles
was higher compared to the 80 nm particles. Particles
were found in secondary organs at fractions of <0.002 and
0.001 of deposited dose of the smaller and larger particles,
respectively [16]. This was confirmed in a follow-up study,
in which translocation of 20 nm particles to secondary
target organs was higher compared to 80 nm particles
[17]. Another group found that translocation of gold
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but greater for the 2 nm particles compared to the larger
particles [34]. Similarly, after exposure to gold nanopar-
ticles of 7 nm and 20 nm primary size (both having an
agglomerate size of 45 nm), the 7 nm particles were more
subject to translocation and more heavily distributed in
secondary organs than the larger particles. However, the
20 nm particles were detected at higher levels in the aorta
and faeces [26]. In contrast to these findings, when rats
were exposed via inhalation to aluminum oxyhydroxide
nanoparticles of 10 nm and 40 nm primary size (1.7 μm
and 0.6 μm aerodynamic size), the translocation of the lar-
ger particles was higher compared to the smaller particles.
The particles translocated to the lung-associated lymph
nodes but were not detected in any other secondary organ
[13]. The larger aerodynamic size of the 10 nm particles
probably resulted in a lower deposited fraction in the
alveoli compared to the 40 nm particles, which might ex-
plain the higher translocation rate of the 40 nm particles.
Overall, single nanoparticles and agglomerates of <100 nm
are less efficiently phagocytized by alveolar macropha-
ges compared to microparticles or large agglomerates
of >1 μm [69,70,73]and less efficiently cleared by muco-
ciliary clearance [71,72]. Increased retention of nanoparti-
cles in the lung may damage the lungs or may result in
the translocation of the nanoparticles to secondary organs.
It is important to note that in general, clearance by trans-
location reported in the studies is very low, below 0.5% of
the exposure concentration [16,17,27,34]. Over time, this
may still accumulate to significant amounts for persistent
nanoparticles, but no studies are available to demonstrate
this.
Shape
Clearance from the lung is notably influenced by the
shape of the particles [9]. Rigid fibres may more readily be
entrapped in the lungs compared to spherical particles
[74]. In rat inhalation studies, longer fibres appeared to be
more difficult to clear than shorter ones [75]. Fibres longer
than about 15–20 μm cannot be completely phagocytized
by individual lung macrophages [76], resulting in frus-
trated phagocytosis in which adjacent cells attempt to
phagocytize the same fibre [77]. In mice exposed to silver
nanowires of different lengths via pharyngeal aspiration,
shorter fibres with a length of 3, 5 and 10 μm could be
completely phagocytized by alveolar macrophages whereas
longer fibres with a length of 14 μm induced frustrated
phagocytosis [39].
Exposure of mice to anatase titanium dioxide particles
of various shapes (nanospheres, short nanobelts of 1 –
5 μm, and long nanobelts of 4 – 12 μm) resulted in a lung
deposition of 135 μg both for the animals exposed to
nanospheres and long nanobelts, but clearance was af-
fected by particle shape. At 112 days after exposure, thelung burden was significantly lower in mice exposed to
nanospheres (45 μg) than in those exposed to long nano-
belts (60 μg) [38]. Nanoplatelets can also impair clearance
compared to spherical nanoparticles. After intrapleural
instillation in mice, graphene nanoplatelets induced pro-
longed retention in the pleural space whereas carbon
black did not [40]. The study shows that the aerodynamic
diameter of graphene nanoplatelets is much smaller than
the projected area diameter, giving the platelets the oppor-
tunity to deposit in the alveoli [40]. In conclusion, long
fibre-like or platelet nanoparticles are more readily en-
trapped in the lung and are more difficult to clear than
shorter ones or spherical nanoparticles [38-40,76,77].
Chemical composition
Long-term exposure to diesel exhaust particles at con-
centrations of 0.8, 2.5, 4.5 and 7 mg/m3, carbon black at
11.6 mg/m3, and titanium dioxide (80% anatase, 20%
rutile) at 10 mg/m3 resulted in impaired clearance from
the lungs for all three types. After 18 months of expos-
ure and a recovery period of 3 months, lung clearance
was still impaired and had not returned to normal levels.
At that time point, the retained masses of the test mate-
rials were 47.7 mg/lung, 45.2 mg/lung and 37.8 mg/lung
for diesel exhaust, carbon black and titanium dioxide,
respectively. The strongest effect on lung clearance was
caused by exposure to the highest concentration of
diesel exhaust particles compared to similar concentra-
tions of titanium dioxide and carbon black [21]. The
effects after short-term inhalation of 5 days were tested
for two types of titanium dioxide (anatase or 80% ana-
tase with 20% rutile), zirconium dioxide, cerium dioxide,
zinc oxide, silicon dioxide, carbon black, and multi-
walled carbon nanotubes [22]. All nanoparticles were
tested at concentrations of 0.5, 2.5 and 10 mg/m3, except
for titanium dioxide nanoparticles that were tested at 2,
10 and 50 mg/m3 and multi-walled carbon nanotubes
that were tested at 0.1, 0.5 and 2.5 mg/m3. Only expo-
sure to anatase titanium dioxide, at the highest concen-
tration tested, resulted in reduced lung clearance: the
retained dose was 1635 μg directly after 5 days inha-
lation and 1340 μg at day 21–29 [22]. For the other
nanoparticles tested, the retained doses in the lungs
were at least a factor 4 lower, which might be explained
by the lower exposure concentration.
Regarding translocation, the accumulation of carbon-
iridium particles in secondary organs was lower com-
pared to similar-sized iridium particles after inhalation
[17]. When rats were exposed to either 30 nm iron oxide
particles (8.5 mg/kw bw) or 20 nm zinc oxide particles
(2.5 mg/kg bw), there were differences in translocation
rate and distribution in the body. After 12 hours of ex-
posure, zinc was detected in the liver, and after 36 hours,
iron was detected in the liver and zinc was detected in
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tinction between particles and ions, but can likely be
explained by differences in dissolution rates. Overall,
clearance and translocation rates differ depending on the
chemical composition of the nanoparticles.
Surface charge
Surface charge of nanoparticles may also influence their
translocation rate. Endogenous proteins like albumin
adsorb to the surface of charged nanoparticles, thereby
increasing their hydrodynamic size, altering their surface
charge [78,79], and decreasing their surface reactivity
and translocation rate [20]. The higher the surface
charge density, the more proteins are adsorbed [80]. On
the other hand, zwitterionic or neutral organic coatings
prevent adsorption of serum proteins [81]. Examples are
zwitterionic cysteine and polar PEG ligands that lead to
rapid translocation of nanoparticles to the mediastinal
lymph nodes [20]. Overall, charged particles attract
proteins and thereby reduce their translocation rate
[20,80,81]. In addition, the attracted proteins can form a
corona around the nanoparticles and alter their recogni-
tion and uptake by alveolar macrophages.
Dissolution in physiological media
Many nanoparticles are insoluble and retain their phys-
ical shape after deposition. Others, like zinc oxide, cop-
per oxide, nickel oxide, iron oxide, silicon dioxide, and
silver nanoparticles can dissolve at various rates. The
epithelium of the respiratory tract is covered with a lin-
ing fluid, and materials that dissolve in this fluid are
readily transferred to the blood [82]. Only a few studies
focused on the relation between particle dissolution and
clearance from the lungs. One study suggests that after
intratracheal instillation, the ability of metals to translo-
cate from the lungs into the systemic circulation appears
to be related to their solubility in water [83]. Another
study showed that for cobalt oxide particles, the in vitro
intracellular particle dissolution rate in alveolar macro-
phages was similar to the in vivo transfer to the blood
[82]. However, when the released ions precipitate and/or
transform, they might not be readily transferred and re-
main in the lungs. Therefore, the correlation between
intracellular particle dissolution and in vivo clearance by
transfer to the blood is only valid for specific particles of
which the intracellular dissolution rate is the limiting
step in their clearance [82]. After deposition, some parti-
cles will be taken up by alveolar macrophages. Phagoly-
sosomes inside the macrophages contain proteolytic
enzymes, oxygen radicals, chelators, precipitators, and a
low pH of about 5, all of which may affect the engulfed
particles. The low pH will increase particle dissolution.
If particles release ions that destabilize the membrane of
the lysosome, lysosomal content can leak and result incell death, releasing the ions from the macrophages into
the lungs. By affecting the barrier function of the lung
epithelium, ions may enable intact nanoparticles to enter
the bloodstream as well [82,84].
Pulmonary inflammation induced by nanomaterials
After deposition in the alveoli, nanoparticles interact
with the alveolar epithelium. Nanoparticles can escape
clearance by alveolar macrophages resulting in pro-
longed interaction with the alveolar epithelium [85]. At
a high deposited dose of nanoparticles, there is epithelial
injury, the immune system will treat the presence of the
particles as a threat and inflammation ensues. As a re-
sponse to the epithelial injury, there is an influx of neu-
trophils into the alveolar region [86-88]. The epithelial
cells generate chemotactic factors that stimulate the
migration of macrophages [89]. A prolonged exposure of
epithelial cells to nanoparticles may result in hyper-
secretion of chemo-attractants into the alveolar space. It
is possible that this may disrupt the normal chemotactic
gradient within the lung and result in particle-laden
macrophages remaining within the respiratory region
instead of migrating to the mucociliary escalator for
clearance [90].
The effect of nanomaterials after inhalation that is re-
ported most often is that of pulmonary inflammation,
characterized by an influx of polymorphonuclear neutro-
phils, which may be transient or persistent [10-13,15,18,
21-25,28-31,33,36-38,42-44]. At the cellular level, nano-
particle exposure can induce oxidative stress by the pro-
duction of reactive oxygen species (ROS), which may be
generated directly by particle structures in or near the cell
or may arise more indirectly due to the effects of inter-
nalized particles on mitochondrial respiration [91] or the
depletion of antioxidant species within the cell [92]. Oxi-
dative stress can damage cells by peroxidising lipids, indu-
cing inflammation, and altering proteins and DNA [93]. It
can mediate a number of processes in the cells, such as
apoptosis, DNA adduct formation, and pro-inflammatory
gene expression [94]. All of these have been reported fol-
lowing exposure to some types and concentrations of
nanoparticles [43,95-98]. Therefore, ROS production is
considered the main underlying biochemical process in
nanotoxicology, leading to inflammatory and other sec-
ondary processes that can ultimately cause cell damage
and even cell death [93,99-101]. In the lung, persistent
oxidative stress and inflammation after exposure to
particulate matter are thought to cause fibrosis; in brain
tissue, they are associated with neurodegenerative
diseases [102,103].
The generation of ROS combined with proliferative
signals at sites of persistent inflammation may also result
in an accumulation of genetic defects. It is therefore im-
portant to determine which nanomaterial characteristics
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cause inflammation. Figure 2 illustrates how nanoparticles
can induce adverse effects at the cellular level. It should
be noted that some of the mechanisms illustrated in
Figure 2 are based on in vitro and (in vivo) studies that
use extremely high and therefore unrealistic concentra-
tions. These results provide evidence for the mechanism
behind the observed toxicity. However, they should be
evaluated using lower concentrations that resemble realis-
tic inhalation exposure conditions. The mechanistic path-
ways that operate at low realistic doses might be different
from those operating at very high doses when the organ-
ism’s defences are overwhelmed [52].
Particle size and surface area
Several in vivo studies compared the effect of particle
size on pulmonary inflammation after inhalation or
intratracheal instillation. Ultra-fine anatase titanium dio-
xide particles of 20 nm induced pulmonary inflamma-
tion after intratracheal instillation in rats and mice at
lower mass concentrations compared to titanium dioxide
particles of 250 nm [10]. Moreover, the onset of the in-
flammation was earlier in the 20 nm group. However,
when the dose was expressed as surface area (measured
by the method developed by Brunauer, Emmett, and
Teller (BET) [105]), the dose–response curves over-
lapped [10], indicating that lung inflammation isFigure 2 Suggested mechanisms underlying nanoparticle-induced res
nanoparticle-induced responses potentially lead to altered tissue function a
result in the release of mediators and oxidative stress, which may lead to mitodetermined by the total administered surface area. In an-
other study, mice were intratracheally instilled with six
types of carbon particles, with primary particle size ran-
ging from 10 to 50 nm and specific surface area ranging
from 30 to 800 m2/g [36]. Results indicated that particle
surface area, measured by BET method, is the best dose
metric for responses induced by carbonaceous nanopar-
ticles [36]. In yet another study, however, the total sur-
face area as measured by BET differed from the surface
area calculated from particle size, resulting in different
dose–response curves. The number of particles was thus
considered a better dose metric to describe the effect of
carbonaceous nanoparticles after inhalation, and not sur-
face area [106]. These papers show that differences in
measuring surface area of nanoparticles and differences
in the analysis of experimental data can have a major in-
fluence on the results. Still, the studies show a clear ef-
fect of particle size in the induction of pulmonary
inflammation, regardless if total surface area or particle
number is the best dose metric to describe the effect.
Also in other studies, smaller particles caused more
severe effects than larger particles when the same mass
dose was administered. After intratracheal instillation at a
concentration of 0.5 mg/ml, nano-sized nickel oxide parti-
cles induced lung inflammation and oxidative stress, but
micro-sized nickel oxide particles did not [30]. In addition,
several low-toxicity, low-solubility nanoparticles wereponses at the cellular level. At sufficiently high or persistent levels
nd damage. Uptake of nanoparticles by alveolar macrophages can
chondrial damage, damage to lipids and DNA, and inflammation [104].
Braakhuis et al. Particle and Fibre Toxicology 2014, 11:18 Page 15 of 25
http://www.particleandfibretoxicology.com/content/11/1/18tested in vivo by intratracheal instillation and in vitro on a
human epithelial cell line. The data showed a clear rela-
tion between particle size and pulmonary inflammation as
indicated by neutrophil influx and the induction of pro-
inflammatory mediators; the smaller the particles, the
greater the inflammatory response [107].
To investigate the difference in effect between primary
particle size and agglomerate particle size, anatase titan-
ium dioxide particles of diverse primary and agglomerate
sizes were tested. When primary particles of three sizes
were intratracheally instilled in the lungs of rats at 1.5 mg/
kg bw, smaller particles induced greater inflammation in
the short-term, but for all groups the inflammation was
resolved after one week, regardless of particle size. When
anatase titanium dioxide particles with the same primary
size but different agglomerate size were tested at 5 mg/kg
bw, no clear relationship was observed [31]. When rats
were intratracheally instilled with 50 nm primary gold par-
ticles, their agglomerate of 200 nm, 250 nm primary gold
particles, or their agglomerates of 770 nm, all four groups
showed a mild inflammatory reaction at the tested con-
centration of 1.6 mg/kg bw. No differences were observed
between single particles and their agglomerates [28]. How-
ever, when rats were exposed for 6 hours by inhalation to
titanium dioxide particles with a primary size of 5 nm and
an agglomerate size of 30 nm (small agglomerates) or
190 nm (large agglomerates), there was an effect of ag-
glomerate size on pulmonary inflammation [18]. Expo-
sures to both small and large agglomerates at 7 mg/m3
resulted in a lung burden of 51.3 and 51.5 μg, respectively
and induced increased lactate dehydrogenase (LDH) and
oxidative stress markers. Exposure to the large agglomer-
ates significantly increased the number of neutrophils in
the lungs, while exposure to the small agglomerates did
not [18].
As discussed earlier, the agglomerate size of nanoparti-
cles can change over time. In one study, primary particles
of ultra-fine Teflon fume increased in size over time while
the particle number decreased, indicating agglomeration.
The airborne time allowed ‘aging,’ and after 3.5 minutes of
aging, agglomerated Teflon particles exceeded 100 nm
and no longer caused toxicity; only freshly generated
fumes caused pulmonary inflammation [10].
Particles with a smaller primary size do not always in-
duce more severe effects after inhalation than larger-
sized particles in a similar dose. Ferric oxide particles of
both 22 nm and 280 nm primary size induced dose-
dependent pulmonary inflammation after intratracheal
instillation of 0.8 and 20 mg/kg bw, and both sizes in-
duced oxidative stress [37]. Aluminum oxyhydroxide
particles of 10 nm and 40 nm primary size and 1.7 μm
and 0.6 μm aerodynamic size both induced pulmonary
inflammation after 4 weeks inhalation at the highest
tested concentration (28 mg/m3 exposed concentration,1100 μg of 10 nm and 1800 μg of 40 nm internal dose in
the lungs), with no differences due to particle size [13].
After exposure of mice to 50 μg nano-sized and micro-
sized quartz particles by intratracheal instillation, pul-
monary inflammation was induced in both groups,
without differences due to particle size [33]. Similarly,
cerium oxide particles of 5–10 nm (11 mg/m3), 40 nm
(20 mg/m3) and <5000 nm (55 mg/m3) primary size in-
duced dose-dependent pulmonary inflammation to the
same extent after 28 days of inhalation, perhaps because
their aerodynamic particle size was similar, at 1.03 μm
1.17 μm and 1.40 μm, respectively [29].
Overall, the relation between particle size and pulmon-
ary inflammation is not straightforward, suggesting that
other parameters also drive the response. With applica-
tion of similar mass doses of microparticles and nano-
particles, the latter have a higher total surface area and
total particle number, which may result in increased pul-
monary inflammation. As discussed earlier particles of
different sizes differ in patterns of lung deposition and
clearance, which influence the actual internal dose that
might have an adverse effect on the lungs. For some par-
ticles with the same chemical composition and probably
within a limited size range, deposited particle surface
area seems to be a better predictor for inflammation
than exposure concentrations [10,30,31,36,107].
Shape
The high aspect ratio of long, thin and rigid carbon
nanotubes has raised concern that these carbon nano-
tubes may induce pulmonary responses similar to as-
bestos [108-110]. Carbon nanotubes that are of a curly
and tangled nature rather than being straight fibres will
probably not induce these pulmonary responses. Several
studies indicate that multi-walled carbon nanotubes
(MWCNT) can induce severe pulmonary inflammation,
possibly because of their fibre-shape [41,65,111-114].
One group reported that high-aspect-ratio single-walled
carbon nanotubes were 23-fold more inflammatory
1 day after aspiration in mice than an equal mass of
spherical carbon black nanoparticles. As stated before,
longer rigid fibres cannot be completely taken up by
macrophages resulting in frustrated phagocytosis [39,77].
This can lead to an inflammatory response by continu-
ous release of pro-inflammatory mediators, recruitment
of inflammatory cells, and generation of reactive oxygen
species. In addition, it might disrupt the normal process
of motility in the lungs, leading to accumulation of lon-
ger fibres in the lower respiratory tract [53,77,115]. In
one study, only long nanofibres and long asbestos fibres
elicited sustained inflammation in the pleural space, with
extensive lesion formation and fibrosis along the parietal
pleura [77,116]. There is a cut-off value of 5 μm for long
fibres to induce effects in the pleural space [77,117].
Braakhuis et al. Particle and Fibre Toxicology 2014, 11:18 Page 16 of 25
http://www.particleandfibretoxicology.com/content/11/1/18Besides fibres, other particle shapes can also influence
the toxicity of nanoparticles. After pharyngeal aspiration
in mice, at concentrations ranging from 1.88 to 30 μg,
anatase titanium dioxide short nanobelts and long nano-
belts induced dose- and time-dependent pulmonary in-
flammation while the nanospheres did not. In addition,
there was some accumulation of long nanobelts in the
interstitium suggesting increased interstitial access or
impaired lymphatic clearance of particles with high as-
pect ratio [38]. Wire-shaped silver particles induced a
strong toxicity at similar particle mass, surface area and
number compared to spherical particles on human epi-
thelial cells in vitro. In contrast, the various lengths of
wire did not affect the level of toxicity [118]. These stu-
dies show that fibre-shaped, wire-shaped and nanobelt
particles are more toxic to the lungs compared to sphe-
rical shaped nanoparticles [38,109,118].
Chemical composition
It is plausible that, similar to conventional chemicals,
the chemical composition of nanomaterials can influence
their effect after inhalation exposure. Nanoparticles con-
sisting of relatively toxic materials such as nickel and co-
balt induce severe inflammation, as they have a high
surface-specific activity and a large surface area per unit
mass [119,120]. Ferric oxide and zinc oxide nanoparti-
cles induced serious hepatic lesions in rats when sprayed
directly into the nose twice daily over three days at 8.5
and 2.5 mg/kg bw, respectively. In general, the liver
lesions were more severe in animals treated with zinc
oxide than those treated with iron oxide. Pulmonary in-
flammation and lesions were likewise evident in both ex-
posure groups and tended to be more severe in the
group exposed to iron oxide [23]. However, for both par-
ticle types, effects may have been caused at least in part
by dissolved zinc or iron ions. In a long-term inhalation
study, rats were exposed for 24 months and mice were
exposed for 12 months to similar-sized aerodynamic parti-
cles of diesel exhaust at concentrations ranging from 0.8
to 7 mg/m3, carbon black at 11.6 mg/m3, or titanium di-
oxide at 10 mg/m3 [21]. After 24 months exposure, the
retained doses in the lungs of rats were 63.9 mg/lung,
43.9 mg/lung and 39.2 mg/lung for the highest exposed
concentration of diesel exhaust, carbon black and titanium
dioxide, respectively. Compared to controls, the mean life-
time of the rats was substantially shortened by exposure
to carbon black and titanium dioxide, but not the diesel
exhaust particles. Pulmonary inflammation and lesions
were detected in all exposed animals. Particles of all three
chemical compositions were detected in alveolar macro-
phages and in the alveolar region. After 6 months and
12 months of exposure, no lung tumours were found in
the rats. After 24 months exposure and 6 months recov-
ery, lung tumours were found in rats with all threeexposures: 22% for diesel exhaust, 39% for carbon black,
and 32% for titanium dioxide particles. It is remarkable
that exposure to diesel exhaust resulted in the highest
retained dose in the lungs but did not induce the highest
tumour rate and did not shorten the lifetime of the rats.
In mice, the tumour rate in the exposed groups did not
differ from the controls [21].
After short-term inhalation of five days, differences were
observed in the effects caused by nanoparticles of seven
different chemical compositions [22]. All nanoparticles
were tested at concentrations of 0.5, 2.5 and 10 mg/m3,
except for titanium dioxide nanoparticles that were tested
at 2, 10 and 50 mg/m3 and multi-walled carbon nanotubes
that were tested at 0.1, 0.5 and 2.5 mg/m3. Of these, titan-
ium dioxide, cerium dioxide, zinc oxide, and multi-walled
carbon nanotubes induced dose-dependent pulmonary in-
flammation. For the first three, it was reversible at lower
concentrations and partly reversible at the highest concen-
trations tested. The effects of multi-walled carbon nano-
tubes were irreversible and progressive. Exposure to
zirconium dioxide, silicon dioxide, and carbon black
induced no detectable inflammation at the tested concen-
trations. The nanoparticles that caused pulmonary in-
flammation were retained in the lungs at higher doses
compared to the nanoparticles that did not induce
pulmonary inflammation. After 5 days inhalation, the
retained doses in the lungs were 1635 μg titanium dioxide,
340 μg cerium oxide, 428 μg zinc oxide compared to
200 μg zirconium dioxide, and 93 μg silicon dioxide, for
the highest concentrations tested [22]. After intratracheal
instillation at a concentration of 0.5 mg/ml, nano-sized
nickel oxide particles induced lung inflammation and oxi-
dative stress while nano-sized titanium dioxide particles
did not [30]. It must be noted that titanium dioxide nano-
particles occur in different crystal structures: anatase, ru-
tile or a combination of both. Several in vivo and in vitro
studies showed anatase titanium dioxide induced more
adverse effects than rutile titanium dioxide [121-125]. Ac-
cording to these studies, chemical composition of the
nanoparticles affects their potential to induce pulmonary
inflammation, as would be expected from the different po-
tency of conventional chemicals.
Surface charge
Nanoparticles have different surface charges depending on
the coatings, surfactants, and solvents used in production.
In addition, they may acquire a corona of proteins after
deposition in the lung. The surface charge can be mea-
sured by the zeta-potential, which is the electric potential
created between the charged groups associated with the
surface of a particle and the suspension medium. The
zeta-potential reveals dynamic changes depending on the
pH of the medium and the adsorption of proteins that
form the corona. In most metal oxide nanoparticles, the
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antly positive in an acidic environment of pH 5.6, and
slightly negative when there is a corona of proteins or lung
lining fluid [77]. When nanoparticles encounter biological
fluids containing macromolecules, they attract the oppos-
itely charged ones to form the corona. The surface charge
will change based on the adsorption of those molecules
and proteins, thereby reducing the overall charge of the
nanoparticles [78,79]. When they are phagocytized by al-
veolar macrophages, the proteolytic enzymes and acidic
pH in the phagolysosomes may strip off all or part of the
corona and reveal the naked surface of the particle, restor-
ing its original zeta-potential [126]. If the zeta-potential
has a high positive value, the particle can bind to and
damage membranes [77]. Positively charged nanoparticles
are more easily taken up by lung cells, compared to neu-
tral or negatively charged nanoparticles; they can thus re-
main in pulmonary cells for a long time, which may cause
severe lung injury [20,127]. When nanoparticles with a
high positive zeta-potential interact with the internal face
of the lysosomal membrane, lysosomes can be destabi-
lized, triggering cell death and inflammation [128,129].
Similarly, cationic nanoparticles are known to be more
cytotoxic in vitro than neutral or anionic nanoparticles,
causing lysosomal damage [19,130-132]. After intratra-
cheal instillation of 15 metal and metal oxide nanoparti-
cles in mice at a concentration of 150 cm2/rat, the ability
of the particles to cause acute lung inflammation corre-
lated linearly with their in vitro zeta-potential in an acidic
environment [19]. For the low-solubility particles, zeta-
potential correlated best with the induced pulmonary in-
flammation [19].
Overall, compared to neutral and negatively charged
nanoparticles, positively charged nanoparticles can more
easily be taken up by cells [20,127], leading ultimately to
cell death and inflammation [128,129].
Dissolution in physiological media
Some nanoparticles can dissolve after deposition in the
lungs, leading to formation of ions. When fast-dissolving
nanoparticles are phagocytized by macrophages, the dis-
solution rate may be accelerated, leading to lysosomal de-
stabilisation, cell death, and inflammation, dependent on
the chemical identity of the ions that are released [84]. For
fast-dissolving nanoparticles, the effect is mainly driven by
their chemical composition [77]. Copper ions, zinc ions,
and silver ions are known to have a toxic effect in vitro
[42,130]. Mice were intratracheally instilled with a panel
of 15 metal or metal oxide nanoparticles to relate their
various physicochemical parameters to lung inflammation.
Toxic ions, like copper and zinc caused destabilization of
the lysosomal membrane [19]. In the acidic conditions of
phagolysosomes, nanoparticles of copper oxide, magne-
sium oxide, and zinc oxide showed rapid, completedissolution, while nanoparticles like silver, cerium oxide,
silica, and titanium dioxide showed minimal dissolution
[77]. The pulmonary toxicity of nickel, zinc, and copper
oxide nanoparticles and their aqueous extracts (containing
only ions and no particles) were investigated both in vitro
and in vivo [43]. Results showed that the pulmonary in-
flammation induced by nickel oxide nanoparticles is
caused by the particles and not by nickel ions in the aque-
ous extracts. For zinc oxide and copper oxide, the aqueous
extracts induced effects similar to their corresponding
nanoparticles in vitro. However, in vivo, zinc oxide and
copper oxide nanoparticles caused particle-specific eo-
sinophil recruitment that was not observed after adminis-
tration of their aqueous extracts. In addition, exposure to
the nickel and zinc oxide nanoparticles caused chronic
effects that lasted up to four weeks. No aqueous extract
caused such sustained inflammation, probably because
soluble ions are rapidly cleared from the lungs.
It must be stressed that the dissolution rate of nanopar-
ticles is not a constant factor but depends on particle size,
coating, stability, manufacturing process, and biological
environment. In vivo, released ions may be transported
from the site of generation to other body parts, resulting
in continued dissolution (and thus ion generation) of the
residual nanoparticles. In vitro, dissolution may reach a
maximum under static conditions. Especially for silver
nanoparticles, the literature on their dissolution is contra-
dictory. One study tested agglomeration, sedimentation,
and dissolution of silver nanoparticles in biological media,
finding that they did not dissolve in any of the tested fluids
up to 96 hours incubation [133]. Other researchers report
that silver nanoparticles indeed dissolve over time; the
smaller the particles the faster they dissolve [134].
Whereas the effect of fast-dissolving nanoparticles prob-
ably depends on their chemical composition, the effects of
slow- or partial-dissolving nanoparticles are more difficult
to predict and will depend on the toxicity of the ions and
of the particle that is retained [77].
Hydrophobicity
Nanoparticles can be hydrophilic or hydrophobic, based
mainly on their surface ligands, surfactants, or stabilizers
[130]. Hydrophobic nanoparticles are difficult to disperse
in biological fluids and media, while hydrophilic particles
easily disperse. However, hydrophobicity enhances the
penetration ability of nanoparticles into cell membranes
and nuclear pores through the hydrophobic effect
[93,135], which is the tendency of nonpolar substances
to aggregate in aqueous solution and exclude water mol-
ecules [136]. To investigate the difference in effect bet-
ween hydrophilic and hydrophobic nanoparticles, rats
were exposed to three types of synthetic amorphous
silica: 12 nm particles of hydrophilic pyrogenic silica,
12 nm particles of hydrophobic silica, and 18 nm
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ation exposure for 13 weeks at 1, 6 and 30 mg/m3, the
most pulmonary inflammation was induced in the group
exposed to 12 nm hydrophilic silica, and the least in-
flammation in the group exposed to 18 nm hydrophilic
silica. This is interesting, as both particle types had simi-
lar specific surface areas. It must be noted that the
12 nm hydrophilic silica dissolved quickly over time,
which might have caused its inflammatory effects and
subsequent fast clearance [25]. In a 5-day inhalation
study of three types of synthetic amorphous silica at 1, 5
and 25 mg/m3, the pyrogenic silica (also known as
fumed silica) induced the most pronounced pulmonary
inflammation compared to silica gel and precipitated sil-
ica. The silica gel induced the least pulmonary inflam-
mation. All three had a similar clearance rate [24]. Like
the 13-week study, the 5-day study showed that hydro-
philic pyrogenic silica particles induced more severe
pulmonary inflammation compared to other forms of sil-
ica, indicating that surface hydrophobicity/hydrophilicity
can influence the effect of nanomaterials after inhalation.
However, other particle characteristics, such as solubil-
ity, charge, and aggregation may also play a role.
Surface reactivity
Chemical reactions and leakage of constituents occur at
the surface of nanoparticles. The number of surface mole-
cules increases exponentially when the particle decreases
in diameter. Therefore, nanoparticles have a larger per-
centage of surface molecules compared to their ‘bulk’
counterparts [52,137]. Surface reactivity is the potency of
particles to react with the immediate environment by in-
ducing reactive oxygen species (ROS), leakage of constitu-
ents, and other biochemical reactions. It depends on the
chemical composition, shape, size, solubility, and surface
area of particles [96,138], and is generally determined by
measuring the induction of ROS, as pulmonary inflamma-
tion is thought to be caused by ROS generation at the
nanoparticle surface [93,99-101].
In a 5-day inhalation study, rats were exposed to 20–
30 nm titanium dioxide (mixture of 70% anatase and
30% rutile) at a concentration of 88 mg/m3, pigmentary
200 nm titanium dioxide (rutile) at a concentration of
274 mg/m3, or quartz particles at a concentration of
96 mg/m3. The exposure resulted in a retained dose in
the lungs of 2025 μg 20–30 nm titanium dioxide,
9182 μg 200 nm titanium dioxide, and 2190 μg quartz at
the end of exposure. The two titanium dioxide particles
differ in their crystallinity and surface area; the pigmen-
tary titanium dioxide and the quartz particles differ in
chemical composition and surface reactivity. All three
particle types induced pulmonary inflammation, but it
was reversible after 14 days for both types of titanium
dioxide while being not reversible for the quartz. Therecovery from effects seemed faster for the smaller titan-
ium dioxide nanoparticles compared to the larger ones,
which could reflect the higher mass lung burden of the
larger particles caused by their higher exposure mass
concentration. Overall, the quartz particles induced the
most pulmonary inflammation despite their deposited
surface area being the smallest. Therefore, the authors
conclude that surface reactivity is more important than
surface area in nanoparticle toxicity [44]. The same con-
clusion was reached when ultrafine titanium dioxide par-
ticles, differing in specific surface area and in surface
reactivity, were tested in rats after intratracheal instilla-
tion at 1 and 5 mg/kg bw. Only the titanium dioxide
particles with the highest surface reactivity induced pul-
monary inflammation [11]. However, those that induced
no pulmonary inflammation were reduced in reactivity
by a coating of silica or alumina. This finding implies
that the rats were exposed to particles with different
chemical composition and that toxicity is determined by
the composition of the surface that comes in contact
with a cell. Similar findings were reported in another
study in which various types of quartz particles were
intratracheally instilled in rats at 1 and 5 mg/kg bw. The
intensity of the resulting pulmonary inflammation was
wide-ranging and not dependent on particle size; surface
reactivity determined the toxicity of nanoparticles rather
than particle size [12]. In vitro, quartz particles had a lar-
ger inflammatory potential compared to titanium dio-
xide and carbon black, although the quartz had a lower
total surface area. The authors concluded that the greater
ability of quartz to cause inflammation is related to its sur-
face oxidative activity. For particles with a highly reactive
surface like quartz, lower surface-area doses are required
to induce pro-inflammatory responses [139].
Information on the surface reactivity of nanoparticles
combines information on the effects of the chemical com-
position, shape, size, solubility, and surface area of the
nanoparticles [96,138]. In addition, several studies found a
correlation between surface reactivity and pulmonary in-
flammation [11,12,44]. Therefore, surface reactivity might
be the most important nanoparticle characteristic deter-
mining their effect.
Methods to determine surface reactivity of nanomaterials
Several methods are available to determine surface re-
activity of nanomaterials. As pulmonary inflammation is
thought to be caused by the generation of ROS at the
nanoparticle surface [93,99-101], this process has been
studied in both cell-free and cellular conditions. The
oxidation potential of nanoparticles in cell-free condi-
tions can be easily analysed by electron spin resonance
(ESR) techniques. These techniques use a spin-trapping
agent to detect the nanoparticle-elicited generation of
hydroxyl radicals in the presence of hydrogen peroxide.
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tential of the particles in the reducing environment of
cells or extracellular fluid [96]. One study observed that
the acellular potential of 20 nm silver nanoparticles to
generate ROS was lower compared to larger silver nano-
particles, whereas its cellular potential was higher [140].
Another study observed that carbon black generated
substantial amounts of ROS under cell-free conditions,
but titanium dioxide nanoparticles did not. However,
both showed a comparable dose-dependent capacity to
produce intracellular ROS [141]. These results suggest
that the generation of ROS might be an indirect effect
of the interaction of the nanoparticles with cellular
components. As it occurred in macrophages only at
concentrations above those that reduce their metabolic
activity, ROS generation may have been a secondary ef-
fect rather than causing the onset of cytotoxicity [140].
Therefore, the inability of nanoparticles to produce ROS
in cell-free systems does not rule out their potential to
produce intracellular oxidative stress [141]. Measuring
the intracellular induction of ROS after nanoparticle ex-
posure in vitro might be a way to categorize nanoparti-
cles into hazard groups. However, there is no validated
in vitro assay available to test all types of nanomaterials.
The intracellular induction of ROS can be measured
using ESR techniques in combination with in vitro cel-
lular exposure or using the 2’-7’-dichlorodihydrofluore-
cein diacetate (DCFH-DA) assay. The DCFH-DA assay
uses a fluorescent probe to visualize the induction of
ROS in cells after exposure to nanoparticles. Another
method is the free radical analytical system (FRAS)
assay that measures the formation of reactive oxygen
metabolites (ROM) after exposure to nanoparticles. Be-
sides measuring ROS generation, the surface reactivity
of nanomaterials can be measured based on how well
they serve the purpose for which they were designed.
For example, some nanomaterials are added to a pro-
duct for their catalytic potential, and others for their
anti-bacterial activity or UV absorbance. For such nano-
materials, the surface reactivity required to catalyse
reactions, kill bacteria, or absorb UV can be used to deter-
mine the actual surface reactivity of the materials. Other
methods to measure surface reactivity are the erythrocyte
haemolysis assay [142,143] and the vitamin C yellowing
assay [11,144]. The erythrocyte haemolysis assay measures
the amount of haemoglobin released after exposure of red
blood cells to nanoparticles, and the vitamin C assay mea-
sures the chemical reactivity of nanoparticles toward an
anti-oxidant. Neither of the assays can measure the sur-
face reactivity of all types of nanomaterials.
Summary and conclusions
Although size has been put forward as an essential par-
ameter to predict the pulmonary inflammation causedby nanomaterials, many other factors modulate the out-
comes of toxicity studies. Our conclusions on the physi-
cochemical characteristics of nanomaterials that affect
pulmonary inflammation are listed below.
 The induction of pulmonary inflammation by
nanomaterials depends largely on the extent of
deposition in and clearance from the lungs.
 No single particle property can be identified as the
most important in the induction of pulmonary
inflammation by nanomaterials, as various
properties affect different stages of the events
leading to pulmonary inflammation.
 Surface reactivity might be the best predictor for a
nanomaterial’s potential to induce pulmonary
inflammation.
 There is a lack of information on the potential
effects of long-term inhalation exposure to persistent
nanomaterials, in terms of a potential delayed onset
of pulmonary inflammation and translocation to
secondary organs.
One essential step in predicting the risk of adverse hu-
man health outcomes based on experimental studies is to
elucidate the deposition and clearance of nanomaterials.
These processes are largely driven by the physical charac-
teristics of nanoparticles and need to be taken into account
when investigating to what extent specific nanomaterial
characteristics affect pulmonary inflammation.
Agglomerate particle size and density are the most
dominant of all the nanomaterial characteristics that
affect lung deposition. Using these values as input, the
dose of nanomaterials in the lung can quite accurately
be predicted by the Multiple Pathway Particle Dosimetry
model (MPPD model). However, it should be realized
that other nanomaterial characteristics affecting lung de-
position have not been investigated to the same extent,
and results of the MPPD model should be interpreted
with caution. Primary size, shape, chemical composition,
charge, and dissolution rate can all affect clearance rate.
Many physicochemical characteristics of nanomaterials
influence the severity of pulmonary inflammation, and no
unifying metric can be identified based on the current
available evidence. Some studies use rather high and un-
realistic exposure concentrations, which might lead to
lung particle overload conditions and severe adverse ef-
fects in laboratory animals, which will probably not occur
under realistic in vivo exposure conditions in humans
[67]. Results on the influence of primary particle size
on pulmonary inflammation after inhalation are rather
contradictory. Some studies report increased pulmonary
inflammation after exposure to nanoparticles compared to
larger micro-sized particles [10,30,31,36,107], while others
report no difference [13,37]. As discussed earlier, both the
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lung deposition, clearance, and translocation. Therefore,
inhalation studies should measure the actual deposition
and retention of particles in the lung, preferably as total
mass, surface area, and number dose. By comparing the
effects of these local doses for the different particle sizes,
conclusions can be drawn about the role of size in pul-
monary inflammation. For some particles of the same
chemical composition (and probably within a limited size
range), the deposited surface area seems to be a better
predictor for inflammation than mass exposure concen-
trations [10,30,31,36,107]. In addition, nanoparticles tend
to agglomerate or even aggregate, changing particle size
and available surface area. Information on the influence of
particle agglomeration and aggregation on pulmonary in-
flammation is very limited.
Besides particle size, other nanoparticle characteristics
influence deposition, clearance, and induction of pul-
monary inflammation (Figure 3). All these characteristics
affect different stages of the events leading to pulmonary
inflammation; no single characteristic can be identified
as the most important in the induction of pulmonary in-
flammation by nanomaterials.Figure 3 Nanomaterial characteristics resulting in increased lung dep
pulmonary inflammation. The figure shows the physico-chemical charact
the alveoli (left panel): Nanoparticles with a primary/agglomerate size of <1
density, will deposit efficiently in the alveolar region. Non-hygroscopic nan
chance to reach the alveoli. 2) Impaired clearance rate (middle panel): Parti
nano-fibres and –platelets are less efficiently cleared compared to spheres,
attract proteins and reduce their clearance, and none or slowly dissolving n
nanoparticles. 3) The induction of pulmonary inflammation (right panel): Af
all influence the induction of pulmonary inflammation. Cationic particles ar
ions, and nanoparticles with a high surface reactivity can damage the lungMeasuring the surface reactivity of nanoparticles
might be the best way to predict the toxicity of nanopar-
ticles because it combines information on the effects of
the chemical composition, shape, size, dissolution rate,
and surface area of the particles [96,138]. A nanoparti-
cle’s surface reactivity depends on the exposure medium,
in which proteins or other macromolecules might attach
to the surface of the nanoparticles. As nanomaterials can
differ in all physicochemical characteristics, surface re-
activity should be measured separately for each type of
nanomaterial in the appropriate medium. Since there is
no validated in vitro assay available to test all types of
nanomaterials, a high-throughput in vitro assay should
be developed and validated to determine the intracellular
production of ROS after nanoparticle exposure. Still, animal
studies are needed to validate the assays, as surface reactiv-
ity in vitro may differ from surface reactivity in vivo, when
nanoparticles react with macromolecules in the body and
where cellular concentrations are much lower.
If surface reactivity indeed turns out to be the best pre-
dictor for the toxicity of nanomaterials, it could be used to
categorize nanomaterials into hazard groups. This might
help reduce animal testing and speed up risk-assessmentosition (in alveoli), impaired clearance rate, and the induction of
eristics of nanoparticles that result in 1) Increased lung deposition in
00 nm, or an agglomerate size between 100 nm and 1 μm with a high
oparticles will not grow in size by water uptake, resulting in a higher
cles/agglomerates of <100 nm are less efficiently phagocytised,
chemical composition influences clearance rate, charged nanoparticles
anoparticles are less efficiently cleared compared to fast dissolving
ter deposition of nanoparticles in the alveoli, the shown characteristics
e easily taken up by cells, fast dissolving nanoparticles can release toxic
s.
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case basis. In addition, if a universal unit of surface re-
activity can be defined, it can be included in the dose
metric of nanomaterials. Still, while surface reactivity and
the ability of nanomaterials to produce oxidative stress ap-
pear to be important predictors for toxicity in the lung,
the effects of other nanomaterial characteristics should
not be ruled out completely. Not all nanomaterial charac-
teristics have been investigated to the same extent, and
new types of nanomaterials are continuously being de-
veloped, taking on more complex forms that may be
associated with new mechanisms of toxicity. A close col-
laboration between developers of nanomaterials and nano-
toxicologists is necessary for the development of new
nanomaterials with promising benefits and low risks.
Although very little is known on the exact clearance
rates and retention of nanoparticles in the lungs, there is
concern that non-soluble nanoparticles will be retained
in the lungs and secondary organs for years. The phago-
cytosis of nanoparticles by macrophages is slower com-
pared to microparticles [69,70,72], and nanoparticles
deposit deeper in the lungs, where the clearance is
slower due to increased pathway length and decreased
mucous velocity [59]. A low-level but longer-lasting or
repeated exposure might enable delayed or slowly devel-
oping pulmonary inflammation that is not resolved over
time. Compared to larger particles, increased retention
of nanoparticles may damage the lungs or may result in
the translocation to secondary organs. It is important to
note that in general, translocation to the systemic circu-
lation is very low, below 0.5% of the exposure concentra-
tion [16,17,27,34]. It is not clear if there is a cut-off
point in particle size beyond which particles can no lon-
ger translocate; under overload conditions, even larger
particles might translocate.
Long-term animal studies are very expensive; there-
fore, there is a great need for alternative methods or
new ways of combining information to predict long-
term accumulation and effects of nanomaterials in the
body. Even for short-term effects, not all characteristics
can be studied in detail in animal studies, because the
variation in nanomaterials is just too large. Therefore,
alternative methods need to be developed for high-
throughput screening of nanomaterials. Some co-culture
in vitro systems have been developed that mimic the
lung barrier [145-149] and hold promise for testing
nanomaterials with diverse characteristics, although par-
allel in vivo studies to demonstrate their predictive value
are often lacking. Finally, human epidemiological studies
conducted in the workplace, for example, can provide
useful information on the effects of nanomaterials after
inhalation.
Since no single nanoparticle property can be identified
as the most important in the induction of pulmonaryinflammation, we have some recommendations for fu-
ture research listed below. The ultimate goal is to
categorize nanomaterials according to their characteris-
tics, which would be of immense value for the risk as-
sessment of these wide-ranging and fast-developing
products.
 The impact of a nanomaterial characteristic should
be systematically tested in different experimental
setups by using a number of different nanomaterials,
varying only in a single physicochemical
characteristic e.g. surface reactivity, and analysed by
controlling for other variables such as size and
chemistry.
 Surface reactivity should be investigated as a
valuable predictor for a nanomaterial’s potential to
induce pulmonary inflammation.
 The data from studies that systematically tested a
single nanomaterial characteristic can be combined
into a large data set to carry out multivariate
analysis to determine potential combinations of
characteristics that are important in affecting
pulmonary inflammation.
 Agglomerate particle size should be measured as
closely as possible to the site of exposure in animal
studies or in occupational exposure settings in order
to accurately predict the lung deposition by the
particle dosimetry models such as the MPPD model.
 Nanomaterial characteristics should be measured in
the appropriate medium, because reaction with
macromolecules in biological fluids will change
nanoparticle characteristics and thereby their
cellular uptake and effect.
 There is a need to generate data on biodistribution
and accumulation of nanomaterials upon long-term
exposure, as well as the induction of toxic effects, to
assess which of the physicochemical properties
have the largest influence on delayed or chronic
pulmonary inflammation.
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